Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCAGN01876 with Immune Therapies in Advanced Malignancies
NCT03277352Phase 2Terminated
- Sponsor
- Incyte
- Start
- Nov 2017
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of INCAGN1876 in solid tumor (advanced stage), metastatic cancer, melanoma, renal cell carcinoma (RCC), urothelial carcinoma (UC), sponsored by Incyte. Started Nov 2017; status: terminated.
02
Drugs
INCAGN1876
03
Conditions
solid tumor (advanced stage)metastatic cancermelanomarenal cell carcinoma (RCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03277352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03277352.